CellPoint B.V.

Galapagos is to launch its first US-based clinical trial of its point-of-care CAR-T technology, which it hopes can be a game-changer in oncology. The novel CAR-T technology has been Galapagos’s brigh

After a long and distinguished career as a biopharma pioneer and leader, most notably his decade as Johnson & Johnson 's chief scientific officer, Paul Stoffels was in late 2021 looking forward to hi

R&D Whiplash At GSK GSK plc CEO Emma Walmsley made her debut at J.P. Morgan five years ago, outlining an ambitious strategy to turn the company into an oncology powerhouse. That vision has not becom

After a string of failed drug candidates from its in-house R&D, Galapagos CEO Paul Stoffels has unveiled a new focus on immunology and oncology for the company, along with plans for more acquisition